Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: ViroPharma Inc.
So what: The FDA declined industrial-scale manufacturing of Cinryze, which treats a fatal genetic disorder called hereditary angioedema. Regulators are looking for more information after observations at pre-approval inspections and a review of the process.
Now what: The company still plans to move forward with higher production assuming risk moving forward. After pummeling the stock 17% in pre-market trading, the stock is up significantly on the day. The risks seem minimal going forward, so barring further setbacks I view this dip as a short-term buying opportunity.
Interested in more info on ViroPharma? Add it to your watchlist here by clicking here.